Skip Navigation



Annals of Oncology Advance Access published online on November 4, 2009
Annals of Oncology, doi:10.1093/annonc/mdp487
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fernández de Larrea, C.
Right arrow Articles by Carreras, E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fernández de Larrea, C.
Right arrow Articles by Carreras, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Salvage chemotherapy with alternating MINE–ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation

C. Fernández de Larrea1, C. Martínez1,*, A. Gaya1, A. López-Guillermo1, M. Rovira1, F. Fernández-Avilés1, M. Lozano2, F. Bosch1, J. Esteve1, B. Nomdedeu1, E. Montserrat1 and E. Carreras1

1 Department of Hematology
2 Department of Hemotherapy, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain

* Correspondence to: Dr C. Martínez, Department of Hematology, Institute of Hematology and Oncology, Hospital Clínic of Barcelona, Villarroel 170, 08036 Barcelona, Spain. Tel: +34-93-227-54-28; Fax: +34-93-227-54-84; E-mail: cmarti{at}clinic.ub.es

Background: High-dose chemotherapy (HDT) followed by autologous stem-cell transplantation (ASCT) is considered the gold standard in the treatment of patients with relapsed or refractory Hodgkin's lymphoma (HL). However, the optimal salvage regimen has not yet been established.

Patients and methods: We retrospectively analyzed the efficacy and toxicity of MINE (mesna, ifosfamide, mitoxantrone, and etoposide) alternated with ESHAP (etoposide, methylprednisolone, high-dose cytarabine, and cisplatin) in the treatment of 61 relapsed or refractory HL patients after ABVD-based chemotherapy.

Results: Overall, 25 patients (41%) achieved a complete response (CR), 23 (38%) a partial response (PR), 4 (7%) a stable disease, and 8 (13%) progressed for an overall response rate of 79%. Response to first-line chemotherapy was the most important prognostic factor for response to MINE–ESHAP (P = 0.041). No grade 4 extrahematologic toxic effects or toxic deaths were observed. Adequate peripheral blood stem-cell collection was achieved in 56 of 59 (95%) mobilized patients. Overall survival and event-free survival after HDT and ASCT were significantly higher for patients achieving CR/PR in comparison with those refractory to MINE–ESHAP (46% and 35% versus 74% and 69%, respectively).

Conclusion: MINE–ESHAP results in a high response rate with acceptable toxicity in patients with HL having failed ABVD-based treatment.

autologous stem-cell transplantation, ESHAP, Hodgkin's lymphoma, MINE, salvage therapy

Received for publication June 13, 2009. Revision received September 9, 2009. Accepted for publication September 10, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.